Recent pilot trials suggest feasibility and potential efficacy of psychedelic-facilitated addiction treatment interventions. Fifteen participants completed a psilocybin-facilitated smoking cessation pilot study between 2009 and 2015.
Aims:
The aims of this study were as follows: (1) to identify perceived mechanisms of change leading to smoking cessation in the pilot study; (2) to identify key themes in participant experiences and long-term outcomes to better understand the therapeutic process.
Methods:
Participants were invited to a retrospective follow-up interview an average of 30 months after initial psilocybin sessions. Semi-structured interviews were conducted with 12 of the 15 participants. Data were analysed using thematic analysis.
Results:
Participants reported gaining vivid insights into self-identity and reasons for smoking from their psilocybin sessions. Experiences of interconnectedness, awe, and curiosity persisted beyond the duration of acute drug effects. Participants emphasised that the content of psilocybin experiences overshadowed any short-term withdrawal symptoms. Preparatory counselling, strong rapport with the study team, and a sense of momentum once engaged in the study treatment were perceived as vital additional factors in achieving abstinence. In addition, participants reported a range of persisting positive changes beyond smoking cessation, including increased aesthetic appreciation, altruism, and pro-social behaviour.
Conclusions:
The findings highlight the value of qualitative research in the psychopharmacological investigation of psychedelics. They describe perceived connections between drug- and non-drug factors, and provide suggestions for future research trial design and clinical applications.
BelserABAgin-LiebesGSwiftTCet al. (2017) Patient experiences of psilocybin-assisted psychotherapy: An interpretative phenomenological analysis. J Humanist Psychol57: 354–388.
2.
BogenschutzMPJohnsonMW (2016) Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry64: 250–258.
3.
BogenschutzMPForcehimesAAPommyJAet al. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol29: 289–299.
4.
BogenschutzMPPommyJM (2012) Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Test Anal4: 543–555.
5.
CahillKStevensSLancasterT (2014) Pharmacological treatments for smoking cessation. JAMA311: 193–194.
6.
CampbellJCousineauPBrownSL (1990) The Hero’s Journey: Joseph Campbell on His Life and Work. Vol. 7. Novato, CA: New World Library.
7.
CarbonaroTMBradstreetMPBarrettFSet al. (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol30: 1268–1278.
8.
CicchettiDV (1994) Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess6: 284–290.
9.
CohenJ (1960) Kappa: Coefficient of concordance. Educ Psychol Meas20: 37–46.
10.
Dedoose (2016) Version 7.0.23, Web Application for Managing,Analyzing, and Presenting Qualitative and Mixed Method Research Data. LosAngeles: Socio Cultural Research Consultants. Available at: www.dedoose.com.
11.
De VriesHElliottMNKanouseDEet al. (2008) Using pooled kappa to summarize interrater agreement across many items. Field Methods20: 272–282.
12.
DoblinR (1991) Pahnke’s Good Friday experiment: A long-term followup and methodological critique. J Trans Psychol23: 1–28.
13.
Doering-SilveiraEGrobCSDe RiosMDet al. (2005) Report on psychoactive drug use among adolescents using Ayahuasca within a religious context. J Psychoactive Drugs37: 141–144.
14.
FabregasJMGonzalezDFondevilaSet al. (2010) Assessment of addiction severity among ritual users of Ayahuasca. Drug Alcohol Depend111: 257–261.
15.
FagerströmK (2012) Determinants of tobacco use and renaming the FTND to the Fagerström Test for Cigarette Dependence. Nicotine Tob Res14: 75–78.
16.
FantegrossiWEWoodsJHWingerG (2004) Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol15: 149–157.
17.
FleissJL (1971) Measuring nominal scale agreement among many raters. Psychol Bull76: 378–382.
18.
Garcia-RomeuAGriffithsRRJohnsonMW (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev7: 157–164.
19.
Garcia-RomeuAKersgaardBAddyPH (2016) Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol24: 229–268.
20.
GasserPHolsteinDMichelYet al. (2014) Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-Threatening Diseases. J Nerv Ment Dis202: 513–520.
21.
GriffithsRRJohnsonMWCarducciMAet al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol30: 1181–1197.
GriffithsRRRichardsWAJohnsonMWet al. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol22: 621–632.
24.
GriffithsRRRichardsWAMcCannUet al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl)2006; 187(3): 268–283.
25.
HalpernJH (1996) The use of hallucinogens in the treatment of addiction. Addict Res4: 177–189.
26.
HalpernJHSherwoodARPassieTet al. (2008) Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monit14: SR15– SR22.
27.
HariJ (2015) Chasing the Scream: The Opposite of Addiction is Connection. New York: Bloomsbury.
28.
HaysJTEbbertJOSoodA (2008) Efficacy and safety of varenicline for smoking cessation. Am J Med121: S32–S42.
29.
HeathertonTFKozlowskiLTFreckerRCet al. (1991) The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addict86: 1119–1127.
30.
HendricksPSClarkCBJohnsonMWet al. (2014) Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. J Psychopharmacol28: 62–66.
31.
HendricksPSThorneCBClarkCBet al. (2015) Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol29: 280–288.
32.
JohnsonMWRichardsWAGriffithsRR (2008) Human hallucinogen research: Guidelines for Safety. J Psychopharmacol22: 603–620.
33.
JohnsonMWGarcia-RomeuACosimanoMPet al. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol28: 983–992.
34.
JohnsonMWGarcia-RomeuAGriffithsRR (2016) Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse43: 55–60.
35.
JohnsonMWGarcia-RomeuAJohnsonPSet al. (2017) An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. J Psychopharmacol31: 841–850.
36.
Kabat-ZinnJ (1990) Full Catastrophe Living: Using the Wisdom of your Body and Mind to Face Stress, Pain, and Illness. New York: Delacorte.
37.
KrebsTSJohansenPØ (2012) Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharmacol26: 994–1002.
38.
KrupitskyEMBurakovAMDunaevskyIVet al. (2007) Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs39: 13–19.
39.
MacLeanKAJohnsonMWGriffithsRR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol25: 1453–1461.
40.
MarksDFSykesCM (2002) Randomised controlled trial of cognitive behavioural therapy for smokers living in a deprived area of London: Outcome at one-year follow-up. Psychol Health Med7: 17–24.
41.
McCraeRRCostaPTJr (1985) Openness to experience. In: HoganRJonesWH (eds) Perspectives in Personality. Greenwich, Connecticut: JAI Press, pp. 145–172.
42.
MottilloSFilionKBBélislePet al. (2009) Behavioural interventions for smoking cessation: A meta-analysis of randomised controlled trials. Eur Heart J30: 718–730.
43.
O’BrienCP (2006) Drug addiction and drug abuse. In: BruntonLLLazoJSParkerKL (eds) Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 11th ed.New York: McGraw-Hill, pp. 607–627.
44.
OsmondH (1957) A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci66: 418–434.
45.
PahnkeWN (1969) Psychedelic drugs and mystical experience. Int Psychiatry Clin5: 149–162.
46.
PahnkeWNRichardsWA (1996) Implications of LSD and experimental mysticism. J Relig Health5: 175–208.
47.
RossS (2012) Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatr Clin North Am35: 357–374.
48.
RossSBossisAGussJet al. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol30: 1165–1180.
49.
SavageCMcCabeOL (1973) Residential psychedelic (LSD) therapy for the narcotic addict: A controlled study. Arch Gen Psychiatry1973; 28: 808–814.
50.
StaceWT (1960) Mysticism and Philosophy. Philadelphia, PA: Lippincott.
51.
SedgwickE (2003) Touching Feeling: Affect, Pedagogy, Performativity. Berkeley, CA: Duke University Press.
52.
SessaBJohnsonMW (2015) Can psychedelic compounds play a part in drug dependence therapy?Br J Psychiatry206: 1–3.
53.
SwiftTCBelserABAgin-LiebesGet al. (2017) Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress. J Humanist Psychol57: 488–519.
54.
SykesCMMarksDF (2001) Effectiveness of a cognitive behaviour therapy self-help programme for smokers in London, UK. Health Promot Int16: 255–260.
55.
TønnesenPTonstadSHjalmarsonAet al. (2003) A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med254: 184–192.
56.
WattsRDayCKrzanowskiJet al. (2017) Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-resistant Depression. J Humanist Psychol57: 520–564.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
